Lymphatic filariasis, commonly known as elephantiasis, is caused by thread-like parasitic worms transmitted by mosquitoes. The infection can silently damage the lymphatic system for years before triggering the grotesque limb swelling and genital deformities that give the disease its name. The World Health Organization recommends repeated rounds of mass drug administration, in which entire eligible populations receive antiparasitic medication regardless of infection status, as the cornerstone of global elimination efforts. Samoa, which has battled persistent filarial transmission for decades, deployed triple-drug therapy combining ivermectin, diethylcarbamazine and albendazole in 2018 and again in 2023, making it one of the few countries with two rounds of this intensified regimen.

The research team, led by Helen J. Mayfield of Australian National University and colleagues, designed a study to answer a deceptively simple question: did the second round of triple-drug treatment actually push transmission down? To find out, they conducted household surveys in eight primary sampling units at three time points. The first survey ran six to nine months after the 2018 campaign, the second came four and a half years later in 2023, and the third took place ten months after the 2023 treatment round. Participants aged five and older from randomly selected households were tested for circulating filarial antigen, a marker of adult worm infection, and for microfilariae, the microscopic offspring of adult worms that circulate in the blood and are the form mosquitoes pick up when they bite.

The human data told a sobering story. Antigen prevalence barely moved across the entire study period, sitting at 9.8 percent in 2019, 9.9 percent in 2023 and 10.3 percent in 2024. Statistical comparison of the 2024 and 2023 results confirmed the flat trend, with an odds ratio of 1.0 for antigen positivity, meaning no detectable decrease. Microfilariae prevalence, a more direct marker of active transmission potential, showed a suggestive but statistically uncertain decline, falling from 5.1 percent in 2023 to 3.1 percent in 2024, with an odds ratio of 0.6 whose confidence interval crossed the threshold of significance.

The mosquito data, however, revealed something the blood tests could not. The team deployed BG-Sentinel traps at participating households, sorted captured mosquitoes into species-specific pools, and screened them for filarial DNA using quantitative polymerase chain reaction, a technique known as molecular xenomonitoring. This approach detects parasite genetic material inside the insects themselves, providing a direct readout of how much transmission is actually occurring in the environment. After the 2023 treatment round, the prevalence of qPCR-positive mosquitoes dropped significantly, with an odds ratio of 0.4, meaning positive pools were roughly 60 percent less common than before the campaign.

Looking across the full five-year window from 2019 to 2024, the mosquito-based indicators showed sustained improvement for the species that matters most. Samoa’s filariasis problem is driven largely by Aedes polynesiensis, a day-biting mosquito with peculiar feeding habits that make standard interventions less effective. Prevalence of qPCR-positive Aedes species overall declined with an odds ratio of 0.5, and for Aedes polynesiensis specifically the odds ratio was 0.4, both indicating meaningful reductions over the study period.

The divergence between human and mosquito indicators is the study’s most consequential finding. Antigenemia reflects the presence of adult worms, which can survive for five years or more inside the human body even when treatment has sterilized them. This means antigen prevalence is a lagging indicator, slow to respond to successful interventions, and it may substantially overestimate ongoing transmission in the years immediately after a drug campaign. Microfilariae levels respond faster because the drugs rapidly clear the blood-stage parasites, but human surveys are expensive, logistically demanding and subject to participation bias.

Molecular xenomonitoring sidesteps several of these problems. Mosquitoes sample the transmission process itself, they can be collected in large numbers without requiring individual medical consent, and parasite DNA in mosquitoes reflects recent infections rather than long-lived adult worms. The Samoa results suggest that the 2023 triple-drug round did suppress transmission, as the mosquito data show, even while human antigen levels remained stubbornly unchanged. Had the program relied solely on antigen surveys, officials might have concluded the campaign had failed entirely, potentially triggering unnecessary additional rounds of drug distribution or misdirected resources.

These findings carry weight well beyond Samoa. The Global Programme to Eliminate Lymphatic Filariasis has set 2030 as its target date, and dozens of countries remain in the difficult endgame phase where transmission persists despite repeated treatment. Triple-drug therapy, which adds ivermectin to the traditional two-drug combination, was rolled out precisely because it clears microfilariae more completely and for longer than the standard regimen. Yet Samoa’s experience demonstrates that even this intensified approach, delivered twice with a five-year gap, could not fully interrupt transmission in a setting where the primary vector is unusually efficient at maintaining the parasite.

The authors conclude that mosquito-based indicators can provide a more sensitive measure of intervention impact in the immediate post-treatment period and should complement human serological surveillance for long-term monitoring. As elimination programs worldwide approach the finish line, the Samoa study offers a methodological lesson as much as an epidemiological one: choosing the right yardstick may determine whether hard-won progress is recognized, sustained and ultimately converted into elimination, or dismissed as failure by metrics that cannot yet see the difference.

Subject of Research: Impact of triple-drug mass drug administration on lymphatic filariasis transmission indicators in Samoa

Article Title: Evaluating the impact of triple-drug mass drug administration using human and mosquito-based indicators of lymphatic filariasis in Samoa, 2019 – 2024

Article References: Evaluating the impact of triple-drug mass drug administration using human and mosquito-based indicators of lymphatic filariasis in Samoa, 2019 – 2024. (n.d.). https://doi.org/10.1371/journal.pntd.0013895

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0013895

Keywords: lymphatic filariasis, mass drug administration, Samoa, molecular xenomonitoring, Aedes polynesiensis, triple-drug therapy, neglected tropical diseases, microfilariae, filarial antigen, qPCR, mosquito surveillance, transmission elimination

The study set out to answer a deceptively simple question: how do people living in Debre Elias understand and manage scabies in their everyday lives? To find out, the researchers deployed a rapid ethnographic approach that combined observations with semi-structured interviews. Fieldwork ran from February to July 2022 and produced 57 interviews with a deliberately broad cross-section of the community: people who had experienced scabies, people who had not but considered themselves at risk, local health workers, traditional healers, and government officials. Alongside the interviews, the team carried out participant and non-participant observation in homes, workplaces, social events and treatment facilities, watching how people with and without scabies moved through their daily routines. The researchers also undertook a critical analysis of scabies control and policy documents to understand the official framing of the disease and how it compared with the realities on the ground.

What emerged from this fieldwork is a picture of medical pluralism that official programmes have largely failed to acknowledge. People in Debre Elias routinely navigate both biomedical and traditional healing systems to manage a wide range of health problems, and scabies is no exception. These two systems are not seen as mutually exclusive alternatives but as complementary resources that can be drawn upon in sequence or in parallel. However, the study found that this everyday practice remains largely informal, because traditional healing is often marginalised in official scabies control strategies. The formal system, in other words, pretends that only one of the two pathways exists, even though nearly everyone in the community uses both.

One of the most striking findings concerns the order in which people seek care. Most individuals affected by scabies initially turn to traditional healers, and only afterwards, if the condition persists or worsens, do they seek out biomedical services. This sequencing matters enormously for control programmes. Mass drug administration campaigns assume that affected populations will present themselves to, or be reached by, the formal health system, but if the first port of call is a traditional healer, then a substantial portion of the treatment journey happens outside the sight of programme planners. Delays in reaching effective biomedical treatment can prolong infections, sustain transmission chains within households and communities, and undermine the epidemiological logic of mass treatment, which depends on treating as much of the affected population as possible within a short window to interrupt the cycle of reinfection.

The researchers identify several factors that shape these health-seeking and treatment decisions. The first is the perceived cause of the disease. In many Ethiopian communities, skin conditions such as scabies are understood not solely as biological infestations but as conditions with social, spiritual or moral dimensions, and traditional healers are often seen as better equipped to address those perceived causes. The second factor is the cultural relevance and affordability of traditional medicine. Traditional treatments are embedded in local systems of meaning and are frequently cheaper and physically closer than formal clinics, which may be distant, understaffed, or associated with costs that households struggle to bear. The third factor is limited access to biomedical services themselves, which makes the formal option less practical for many families even when they are aware of it. Together, these forces create a treatment landscape in which traditional healing is not a relic of the past but a rational, accessible and culturally resonant first choice.

From a technical standpoint, the persistence of scabies despite repeated interventions illustrates a well-known problem in neglected tropical disease control: biomedical efficacy does not automatically translate into programme effectiveness. Permethrin and other acaricides used in mass drug administration can kill the mites on treated individuals, but the success of such campaigns depends on high coverage, timely treatment, and simultaneous management of household contacts. When people delay seeking biomedical care because they first visit traditional healers, or when they never enter the formal system at all, the effective coverage of a campaign can fall well below its nominal reach. The mite continues to circulate within and between households, and the region experiences what the study describes as persistent scabies incidence despite the deployment of biomedical interventions intended to contain the disease.

The authors’ conclusion is not that traditional healing should replace biomedical treatment, which remains essential for effectively clearing infestations. Rather, they argue that recognising and engaging with the existing medical pluralism could improve the acceptability, reach and effectiveness of scabies programmes. In practice, this could mean involving traditional healers in outbreak response, creating referral pathways between healers and clinics, and designing health communication that speaks to local understandings of the disease rather than dismissing them. Such collaboration could shorten the delay between the onset of symptoms and effective treatment, extend the reach of campaigns into households that formal services rarely touch, and build the kind of community trust that top-down interventions often lack. The researchers frame this as a shift from co-existence, in which the two systems operate side by side without acknowledgment, to genuine collaboration, in which both are treated as legitimate parts of an inclusive, pluricultural management approach.

The implications extend well beyond one district in Amhara. Scabies is a global problem, disproportionately affecting resource-poor communities in tropical and subtropical regions, and the World Health Organization has included it among the neglected tropical diseases targeted for control. In many endemic countries, the same pluralistic treatment patterns documented in Debre Elias are likely to exist, with traditional healers serving as first-line providers for skin conditions. If control programmes continue to design strategies as though biomedical services were the only relevant pathway, they risk repeating the pattern observed in Ethiopia: technically sound interventions that produce temporary reductions in transmission but fail to achieve durable control. The study suggests that the marginalisation of traditional healing in official strategies is not merely a cultural oversight but an operational liability that directly affects disease outcomes.

There is also a deeper conceptual point in the paper, reflected in its call for an inclusive, pluricultural approach. The researchers argue that supporting pluralistic treatment pathways should be considered an opportunity rather than a liability for scabies control. Traditional healers possess local trust, detailed community knowledge, and established relationships with the very households that biomedical programmes find hardest to reach. Rather than treating these healers as competitors or obstacles, programmes could treat them as partners whose involvement makes interventions more acceptable and more widely used. This reframing challenges a long-standing assumption in global health that the formalisation of care must come at the expense of informal providers, and it aligns with a growing body of research showing that community-engaged approaches tend to outperform purely biomedical ones in settings of deep medical pluralism.

For the people of Debre Elias, the stakes are immediate and physical. Scabies causes intense itching, skin damage from scratching, secondary bacterial infections, and in severe cases complications such as post-streptococcal glomerulonephritis, a kidney disease linked to streptococcal skin infection. Beyond the physical burden, the observational component of the study, which followed people with and without scabies in their homes and public spaces, points to the social weight of a visible, stigmatising skin disease in a close-knit community. An approach that meets people where they actually begin their treatment journey, rather than where programmes wish they would begin it, offers a realistic path toward reducing both the transmission of the mite and the burden carried by affected families. The study’s central message is that the tools for better scabies control may already exist in Debre Elias, distributed across both of its healing traditions, and that the task of public health is to connect them rather than to choose between them.

Subject of Research: Ethnographic research on pluralistic health-seeking behaviour and scabies management in Debre Elias, Ethiopia

Article Title: From co-existence to collaboration: The need to move towards an inclusive (pluricultural) scabies management approach in Debre Elias (Ethiopia)

Article References: Wonde, D., Engdawork, K., Roemer-Mahler, A., Tadele, G., & Trueba, M. (2026). From co-existence to collaboration: The need to move towards an inclusive (pluricultural) scabies management approach in Debre Elias (Ethiopia). PLOS Neglected Tropical Diseases, 20(10), e0014773. https://doi.org/10.1371/journal.pntd.0014773

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014773

Keywords: scabies, Ethiopia, Amhara region, traditional healing, medical pluralism, neglected tropical diseases, mass drug administration, health-seeking behaviour, ethnography, public health, Debre Elias, Sarcoptes scabiei

The study drew on the Child Health with Azithromycin Trial, known as CHAT, a placebo-controlled cluster randomized trial conducted in Burkina Faso in which entire communities were assigned, in a one-to-one ratio, to receive twice-yearly azithromycin or a matching placebo for children aged one to 59 months. The original trial was designed to test whether the antibiotic could prevent deaths from any cause, extending to a high-mortality African setting the earlier evidence from the landmark MORDOR trial in Niger, Malawi, and Tanzania, which had demonstrated a significant reduction in all-cause child mortality with mass drug administration.

The research team, led by investigators at the University of California, San Francisco and the Centre de Recherche en Santé de Nouna in Burkina Faso, asked a deceptively simple question: if azithromycin works by clearing infections, and if infections sap children’s growth, shouldn’t treated children grow better? To answer it, they tracked two standard measures of undernutrition. The first was mid-upper arm circumference, or MUAC, a tape measurement of the upper arm that is widely used in field settings to screen for acute malnutrition because it changes little with age in early childhood and requires no scales. The second was the weight-for-age Z-score, or WAZ, a statistical measure of how far a child’s weight deviates from the expected weight for a healthy child of the same age and sex, calculated here for infants aged one to eleven months.

The scale of the analysis was considerable. The researchers included 80,282 children aged one to 59 months, of whom 26,983 were infants in the one-to-eleven-month age range, drawn from 284 communities. Measurements were collected every six months over the course of the trial, with MUAC taken in all children and weight recorded in infants both to calculate weight-based drug dosing and to enable the nutritional analysis. Because communities rather than individuals were randomized, the statistical methods accounted for clustering, comparing outcomes between the azithromycin and placebo arms at the community level and also following individual children longitudinally over time.

The results were unambiguous in their null finding. At the community level, after 36 months of intervention there was no evidence of any difference in mean MUAC or mean WAZ between villages that had received azithromycin and those that had received placebo. Nor was there any divergence over time: the change in MUAC over the follow-up period showed no difference between arms, with a P-value for interaction of 0.94, and the change in WAZ similarly showed no difference, with a P-value of 0.18. In plain terms, children in azithromycin communities did not have measurably better arm circumference or weight gain than children in placebo communities, either on average or in their growth trajectories.

These findings matter because they speak directly to the leading hypothesis about how mass azithromycin saves lives. The drug, a long-acting macrolide antibiotic, is known to treat a broad range of bacterial infections and some intracellular pathogens, including subclinical infections that never announce themselves with fever or clinic visits. Researchers have plausibly argued that reducing this invisible infectious burden could free up calories and nutrients that would otherwise be diverted to immune defense, allowing children to grow better and thereby lowering their vulnerability to severe illness and death. Undernutrition and infection form a well-documented vicious cycle in early childhood: infection suppresses appetite and impairs nutrient absorption, while malnutrition weakens immune defenses and increases the severity of subsequent infections. Breaking that cycle at the infection end, the reasoning went, should improve the nutrition end.

The CHAT nutritional analysis suggests it did not, at least not in this setting. One interpretation is that the infections most responsible for azithromycin’s mortality benefit are acute, severe episodes rather than the chronic, growth-slowing burden that shapes anthropometric measures over months and years. Mortality in these settings is often driven by rapidly progressive infections such as pneumonia, sepsis, and malaria-associated bacterial coinfections, which can kill a child long before any nutritional pathway could come into play. If azithromycin primarily prevents these fulminant events, its effect on growth would be expected to be small or absent, exactly what the trial observed.

Another possibility is that the dominant drivers of undernutrition in Burkina Faso lie outside the reach of a twice-yearly antibiotic. Diarrheal disease from enteric pathogens, environmental enteric dysfunction driven by repeated exposure to fecal contamination, dietary insufficiency, and malaria are all entrenched in the region, and a macrolide given twice a year may not durably suppress the microbial ecology that stunts growth. Some of the pathogens that most strongly depress growth, such as certain enteroviruses and parasites, are not susceptible to azithromycin at all. The drug’s effects on the gut microbiome, moreover, are complex, and repeated exposure has been associated with rising antimicrobial resistance, a concern that weighs on any expansion of mass distribution programs.

For policymakers, the analysis does not undermine the case for mass azithromycin where mortality benefits have been demonstrated, but it does sharpen the picture of what the intervention can and cannot do. Countries weighing twice-yearly distribution should not expect it to serve as a nutrition program, and investments in the established tools of nutrition improvement, including infant and young child feeding, micronutrient supplementation, food security, and water, sanitation, and hygiene infrastructure, remain essential alongside any antibiotic strategy. The finding also redirects scientific attention toward identifying the actual biological mechanisms behind the mortality reduction, whether through targeted studies of severe infection incidence, biomarkers of systemic inflammation, or cause-of-death ascertainment in future trials.

The study also illustrates the value of embedding mechanistic questions within large mortality trials. Because CHAT already collected MUAC and weight measurements at six-month intervals across nearly three hundred communities, the researchers could test the nutritional hypothesis with statistical power that no standalone study of this size could easily achieve, while respecting the cluster randomized design that guards against contamination between intervention and comparison groups. The trial was registered as NCT03676764 on ClinicalTrials.gov, and the analysis protocol was specified in advance as a secondary objective, reducing the risk of post hoc interpretation. As mass azithromycin programs move from trials toward policy in high-mortality settings, studies like this one will be essential for calibrating expectations, ensuring that a genuinely promising mortality intervention is deployed for what it does, and not credited with benefits the evidence does not support.

Subject of Research: Effects of twice-yearly mass azithromycin distribution on nutritional status in young children

Article Title: Mass azithromycin distribution and nutritional status among children aged 1–59 months: A secondary analysis of a cluster randomized trial

Article References: Ouattara, M., Hu, H., Bountogo, M., Coulibaly, B., Boudo, V., Compaoré, G., Dah, C., Lebas, E., O’Brien, K. S., Arnold, B. F., Lietman, T. M., Sié, A., & Oldenburg, C. E. (2026). Mass azithromycin distribution and nutritional status among children aged 1–59 months: A secondary analysis of a cluster randomized trial. PLOS Global Public Health, 6(10), e0007473. https://doi.org/10.1371/journal.pgph.0007473

Image Credits: AI Generated

DOI: 10.1371/journal.pgph.0007473

Keywords: azithromycin, child mortality, malnutrition, MUAC, weight-for-age Z-score, Burkina Faso, cluster randomized trial, mass drug administration, global health, undernutrition, CHAT trial, PLOS Global Public Health

The research team, led by scientists working with communities across four health districts in the Littoral Region, set out to answer a deceptively simple question: how common are helminth infections among adults, and where are they concentrated? Chronic worm infections are known to cause serious long-term health problems, including lymphatic damage, blindness, anemia, and impaired cognitive development, yet reliable prevalence data for adult populations in this part of Central Africa have been scarce. Without such data, health ministries cannot accurately target interventions or assess whether elimination goals are within reach.

To fill this gap, the investigators recruited adults aged 18 to 65 years who had resided in their communities for at least five years, spanning four health districts that differ dramatically in ecology. Some districts are densely forested, others are wetland forest plantations, and still others are degraded or mosaic plantation landscapes. This environmental gradient was central to the study’s hypothesis: the researchers predicted that infection prevalences would be significantly higher in densely forested and wetland plantation districts compared to areas where forest cover has been fragmented or removed, even after more than twenty years of preventive chemotherapy.

The diagnostic approach was deliberately comprehensive. Participants provided skin snips, thick blood films, and stool samples, which were examined using the Kato Katz technique for intestinal parasites and standard microscopy for blood and skin-dwelling organisms. Demographic data were analyzed in the R statistical environment. The cohort was dominated by farmers, who made up 79.9 percent of participants, with a slight male majority at 52.9 percent, and half of all participants falling between 18 and 49 years of age. This occupational and demographic profile matters, because farming in rainforest and wetland environments brings people into repeated contact with the blackflies, mosquitoes, soil, and water sources that sustain parasite transmission.

The results confirmed the study’s central hypothesis with striking clarity. Yabassi health district, the most densely forested area surveyed, recorded the highest prevalence of Loa loa and Mansonella perstans, two filarial worms transmitted by biting insects that thrive in intact forest ecosystems. Loum health district, characterized by wetland forest plantations, showed higher prevalence for other helminth groups. Overall, 41.9 percent of adults carried at least one infection, with filariasis dominating the picture at 33.3 percent. Onchocerca volvulus, the worm responsible for river blindness, was the single most common parasite at 23.9 percent, followed by M. perstans at 11.9 percent and L. loa at 8.9 percent.

Intestinal parasites, though less prevalent overall at 9.9 percent, revealed an unexpected composition. Capillaria species led at 4.6 percent, ahead of the more familiar Ascaris lumbricoides at 2.9 percent and Trichuris trichiura at 2.7 percent. The trematode findings were equally notable: Dicrocoelium dendriticum, a fluke more typically associated with livestock, was detected in 6.9 percent of participants, while Paragonimus species, lung flukes acquired through eating raw or undercooked freshwater crustaceans, infected 3.5 percent. Taenia species, tapeworms linked to undercooked meat, were the most common cestodes at 3.1 percent. The presence of these less-conventional parasites suggests that transmission pathways in the region extend beyond the classic fecal-oral and vector-borne routes typically targeted by deworming programs.

The epidemiological patterns carried important clues about who is being left behind. Infections were more frequent in males and in individuals over 40 years of age, groups that mass drug administration campaigns rarely reach, since these programs traditionally deliver drugs through schools. Filariasis risk increased with age of 50 years or older and with longer residence in the community, indicating cumulative exposure over decades. Conversely, recent deworming and higher educational attainment both reduced the odds of infection, suggesting that even modest interventions and health literacy can measurably lower risk in this adult population.

One of the study’s most technically interesting observations was the strong statistical association observed among parasites with similar life cycles. Co-infection patterns were not random: worms sharing the same vectors, environmental reservoirs, or transmission routes tended to cluster in the same individuals. This has practical implications for diagnostics and treatment, because a person infected with one forest-associated filarial parasite is substantially more likely to harbor others. It also means that monitoring a single sentinel parasite may provide a reasonable proxy for broader parasitic burden in a given ecological setting, potentially simplifying surveillance in resource-limited districts.

The implications for neglected tropical disease elimination are sobering. Cameroon has committed to eliminating or controlling multiple helminthiases through preventive chemotherapy, the strategy of periodically distributing safe, single-dose drugs such as ivermectin, albendazole, and praziquantel to entire at-risk communities without individual diagnosis. But when programs concentrate on children, adults who remain untreated continue to carry infections, contribute to environmental contamination, and sustain the vector-borne transmission cycle. The authors argue that adults may serve as transmission reservoirs in child-centred programs, effectively reseeding infections in younger generations even as school-based treatment drives down pediatric prevalence.

The study’s conclusions point toward a recalibration of elimination strategy rather than a rejection of existing tools. The researchers recommend monitoring and including adults in preventive chemotherapy programs, promoting regular deworming and community awareness, and adopting a multi-parasite, multi-pathway strategy that addresses the full spectrum of infections circulating in these persistently endemic areas. In practice, this could mean community-wide distribution campaigns that do not stop at the school gate, diagnostics capable of detecting the less familiar parasites such as Capillaria and Paragonimus, and environmental interventions tailored to the forest and wetland ecologies that sustain transmission. As global health agencies push toward the 2030 targets for neglected tropical disease elimination set by the World Health Organization, the message from the Nkam-Wouri River Basin is clear: elimination campaigns that ignore adults may never cross the finish line.

Subject of Research: Epidemiology of helminth infections in adults in rural rainforest communities of Cameroon and implications for neglected tropical disease elimination

Article Title: Epidemiology of helminth infections in adults in rural rainforest communities of the Nkam-Wouri River Basin, Littoral Region of Cameroon: Implications for NTDs elimination using preventive chemotherapies

Article References: Ebob, A. B. O., Gandjui, N. V. T., Lenz, B., Ouam, E., Foyet, J. V., Beng, A. A., Fombad, F. F., Nietcho, F. N., Ritter, M., Karunakaran, I., Mponge, N. N., Nchang, L. C., Wang, C., Tahnteng, F. B., Cho, J. F., Esum, M. E., Katcho, T. D., Hoerauf, A., Hübner, M. P., & Wanji, S. (2026). Epidemiology of helminth infections in adults in rural rainforest communities of the Nkam-Wouri River Basin, Littoral Region of Cameroon: Implications for NTDs elimination using preventive chemotherapies. PLOS Neglected Tropical Diseases, 20(10), e0014780. https://doi.org/10.1371/journal.pntd.0014780

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014780

Keywords: helminth infections, neglected tropical diseases, Cameroon, preventive chemotherapy, filariasis, Onchocerca volvulus, Loa loa, rainforest epidemiology, mass drug administration, parasitology, public health, Nkam-Wouri River Basin

Schistosomiasis, sometimes called bilharzia or snail fever, remains one of the world’s most burdensome parasitic diseases. The worms responsible, Schistosoma mansoni and Schistosoma haematobium among them, spend part of their life cycle in freshwater snails and emerge as infectious larvae that penetrate human skin during contact with contaminated water. Adult worms then settle in the blood vessels around the intestines or the bladder, where female worms release thousands of eggs daily. S. mansoni eggs are shed in stool, while S. haematobium eggs exit in urine, and it is the detection of these eggs in laboratory examinations that reveals an active infection. Chronic disease can damage the liver, intestines, bladder, and kidneys, and in children it is associated with anemia and impaired growth and cognition.

Praziquantel, administered as a single oral dose of 40 milligrams per kilogram of body weight, is the backbone of global schistosomiasis control. Mass drug administration campaigns deliver the drug to entire at-risk communities, often school-aged children, on an annual or biannual schedule. Yet the drug has known limitations: it is highly effective against adult worms but does not act on immature stages, and cure rates vary widely between settings, parasite species, and individual patients. Understanding why those rates vary, and what factors predict treatment failure or rapid reinfection, is essential for programs deciding how often to treat and whom to prioritize.

The new study addressed this question in a setting where both major species coexist, a situation common across much of sub-Saharan Africa but underexplored in treatment trials. The researchers, led by Joule Ntwan Madinga and colleagues working with Congolese and Belgian institutions, randomly selected 388 residents of a village co-endemic for S. mansoni and S. haematobium. Rather than a single before-and-after assessment, they screened every participant every three weeks for nine consecutive weeks, using Kato-Katz thick smear examinations of stool to detect and quantify S. mansoni eggs and urine filtration to detect S. haematobium eggs. Anyone found positive at a visit was treated on the spot with praziquantel at the standard 40 milligrams per kilogram dose.

The baseline picture confirmed how intense transmission is in the village. Just over 60 percent of participants carried S. mansoni, and a nearly identical proportion carried S. haematobium, with 36.6 percent infected with both species simultaneously. More striking were the worm burdens implied by egg counts. People with mixed infections carried far heavier loads than those with single infections: S. mansoni egg counts averaged 200.7 eggs per gram of stool in co-infected individuals versus 70 in those infected with S. mansoni alone, and S. haematobium counts averaged 29 eggs per 10 milliliters of urine versus 9.6. Both differences were highly statistically significant. Co-infection, in other words, is not merely the sum of two independent infections but a marker of substantially greater exposure or susceptibility.

When the researchers examined treatment outcomes, the two species behaved very differently. A single round of praziquantel cured 94.6 percent of S. mansoni infections, with an egg reduction rate of 96.5 percent, meaning that among those not cured, egg output collapsed to a small fraction of pretreatment levels. S. haematobium proved considerably more stubborn: only 62.7 percent of infections were cured by one treatment, although egg reduction still reached 97.5 percent. After three rounds of treatment spaced across the nine-week follow-up, the cumulative cure rate for S. mansoni rose to 93.7 percent, while S. haematobium reached only 75 percent, with cumulative egg reduction rates of 97.5 and 95.6 percent respectively. The pattern suggests that repeated dosing closes much of the gap for intestinal schistosomiasis but leaves urinary schistosomiasis persisting in a quarter of patients.

Co-infection status emerged as a key modifier of these outcomes. Treatment efficacy was significantly higher in people with single infections than in those with mixed infections across every measure the team calculated, including cure rate, egg reduction rate, and their cumulative counterparts. Single infections achieved a cure rate of 76.7 percent compared with 58 percent for mixed infections, a difference with a p-value of 0.01. The authors note that this effect was driven primarily by S. haematobium, the species that already showed weaker cure rates on its own. Age mattered as well: adults and older participants cleared their infections more readily than children under 16, a finding consistent with the possibility that younger children in high-transmission settings carry infections that include immature worms less susceptible to the drug, or that their heavier and more recent exposure leaves them with larger worm populations at treatment.

Perhaps the most reassuring result concerns what happened after treatment. The team tracked reinfection over the follow-up period and found no significant association between a person’s pretreatment co-infection status and their likelihood of becoming reinfected. In other words, carrying both species before treatment makes the initial cure harder to achieve, but it does not appear to make a cured person more vulnerable to picking up new worms afterward. Reinfection in such settings is governed largely by ongoing exposure to contaminated water, which affects the community broadly regardless of an individual’s prior infection history. This distinction matters because it separates a pharmacological problem, which repeated or adjusted dosing might address, from an environmental one, which requires safe water, sanitation, and snail control.

The authors suggest that these findings could help tailor control activities in co-endemic areas. Where both species overlap, programs may need to anticipate lower cure rates, particularly for S. haematobium and for co-infected individuals, and consider more frequent treatment rounds to achieve cumulative cure. The high egg reduction rates even among uncured patients offer some comfort: praziquantel suppresses egg output dramatically, which likely reduces both disease progression and transmission even when worms survive. But the persistence of a quarter of S. haematobium infections after three treatments underscores that a one-size-fits-all annual dose may be insufficient in the hottest transmission foci.

The study also carries implications for how treatment success is measured. Programs typically evaluate mass drug administration using single-dose cure rates, which this research shows can substantially understate the drug’s cumulative effect, especially for S. mansoni, whose cure rate climbed from 62.7 percent after one round to 93.7 percent after three. Conversely, the persistent shortfall for S. haematobium suggests that species-specific monitoring is warranted in mixed-endemic villages. As global goals shift from controlling schistosomiasis toward eliminating it as a public health problem, understanding the fine-grained dynamics of mixed infections, drug efficacy, and reinfection in places like this Congolese village will be central to designing strategies that finally bend the transmission curve.

Subject of Research: Praziquantel efficacy and reinfection dynamics in mixed Schistosoma mansoni and Schistosoma haematobium infections in the Democratic Republic of Congo

Article Title: Impact of praziquantel treatment and early reinfection patterns in a mixed Schistosoma mansoni and Schistosoma haematobium infection focus in the Democratic Republic of Congo

Article References: Madinga, J. N., Roucher, C., Linsuke, S., Baloji, S., Hermy, M., Lutumba, P., & Polman, K. (2026). Impact of praziquantel treatment and early reinfection patterns in a mixed Schistosoma mansoni and Schistosoma haematobium infection focus in the Democratic Republic of Congo. PLOS Neglected Tropical Diseases, 20(10), e0014764. https://doi.org/10.1371/journal.pntd.0014764

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0014764

Keywords: schistosomiasis, praziquantel, Schistosoma mansoni, Schistosoma haematobium, co-infection, Democratic Republic of Congo, cure rate, reinfection, neglected tropical diseases, mass drug administration, Kato-Katz, urine filtration

The research, led by an international team spanning institutions in the United States, Europe, and West Africa, pooled participant-level data from three field studies conducted in 2023 in Mozambique, Ghana, and Benin. Rather than evaluating each test in isolation, the investigators brought together individuals tested across all three countries, creating a combined dataset large enough to support sophisticated statistical modeling. The tests under scrutiny included the commercially available SD BIOLINE Ov16 rapid diagnostic test, which has been widely deployed in onchocerciasis mapping exercises, and two novel assays developed more recently: the DDTD rapid diagnostic test and the GADx rapid diagnostic test. All three are designed to detect antibodies to the Ov16 antigen, a marker of exposure to the parasitic worm that causes river blindness.

The central methodological challenge the researchers confronted is one that plagues much of diagnostic science in neglected tropical diseases: there is no perfect reference standard against which a new test can be judged. The gold standard for confirming an O. volvulus infection involves detecting microfilariae in skin snips, a procedure that is invasive, technically demanding, and critically insensitive in areas where infection levels have been driven down by years of treatment. In low-prevalence settings, a skin snip examination can miss the vast majority of true infections, making it a poor benchmark. Serological tests that detect antibodies offer a more practical alternative, but evaluating their accuracy without a definitive gold standard requires a different analytical approach altogether.

Enter the Bayesian latent class model, the statistical engine at the heart of this study. Latent class models treat the true infection status of each participant as an unobserved, or latent, variable, and then use the patterns of agreement and disagreement among multiple imperfect tests to infer both the true prevalence of infection and the sensitivity and specificity of each test simultaneously. The Bayesian framework adds prior information, formal mathematical expressions of what is already known or believed about test performance before the data are examined. By running the models under multiple specifications, including different priors reflecting laboratory-based and field-based expectations, the researchers could assess how sensitive their conclusions were to the assumptions embedded in the analysis. This approach, while computationally intensive, avoids the circular reasoning that arises when an imperfect test is treated as a perfect reference.

The headline finding concerns the GADx rapid diagnostic test, which emerged as the clear sensitivity leader across every model specification the team examined. Posterior median estimates of its sensitivity ranged from 92.0 percent to 92.8 percent, consistently clearing the 89 percent threshold recommended by the World Health Organization for tests used in decisions to stop mass drug administration. In practical terms, this means the GADx assay missed fewer than one in ten true antibody-positive cases in the studied populations, a level of performance that brings it meaningfully closer to the reliability that elimination programs require. The consistency of this result across alternative model assumptions lends considerable weight to the conclusion, since a finding that survives multiple analytical specifications is far more robust than one that depends on a single set of choices.

The performance of the other two tests tells a more nuanced story. The SD BIOLINE Ov16 test, the only commercially available option among the three, produced posterior median sensitivity estimates above the 89 percent threshold in most models, but fell to 83.2 percent under the field-based prior, a specification that reflects performance expectations drawn from real-world deployment conditions rather than idealized laboratory settings. This inconsistency echoes earlier reports that the SD BIOLINE test shows variable sensitivity when used on whole blood in field conditions. The DDTD rapid diagnostic test, a multi-antigen assay, demonstrated lower sensitivity overall, with posterior median estimates ranging from 86.6 percent to 88.4 percent, placing it just below the recommended threshold. Notably, the researchers tested alternative definitions of a positive result for the multi-antigen DDTD test and found that these did not meaningfully alter its estimated performance, suggesting the result was not an artifact of how positive readings were scored.

Specificity, the ability of a test to correctly identify people who are not infected, presented a different kind of problem. All three tests achieved consistently high specificity estimates, with the highest posterior median reaching 98.8 percent. That figure sounds impressive, and in most clinical contexts it would be. But the WHO-recommended threshold for tests supporting decisions to stop mass drug administration is 99.8 percent, a demanding standard that reflects the consequences of false positives in low-prevalence settings. When transmission has been reduced to very low levels, even a small false-positive rate can generate a misleading picture of ongoing transmission, potentially triggering unnecessary rounds of treatment, wasted resources, and delayed declarations of elimination. None of the evaluated tests, including the high-performing GADx assay, reached that specificity bar on its own.

The implications of this gap are significant for the global elimination agenda. Onchocerciasis programs increasingly rely on serological surveys of children, who should show little or no antibody evidence of exposure if transmission has been interrupted, to guide decisions about stopping treatment. A test that combines high sensitivity with extremely high specificity is essential for these surveys to be trustworthy. The study’s findings suggest that while the novel rapid tests, particularly the GADx assay, represent genuine progress over the existing commercial option, no single test currently available can shoulder the entire burden of an elimination decision. The authors conclude that improved diagnostic tools or complementary testing strategies will be needed, which could involve combining tests in sequence, using different sample types, or integrating serological data with entomological surveillance of the blackfly vectors that transmit the parasite.

The geographic breadth of the underlying data strengthens the study’s relevance across the African continent, where the vast majority of onchocerciasis burden is concentrated. Field studies in Mozambique, Ghana, and Benin captured diverse epidemiological settings, from areas with historically intense transmission to those where control efforts have been sustained for many years. Pooling participant-level data, rather than combining summary statistics from separate analyses, allowed the Bayesian models to account for heterogeneity across sites and to borrow statistical strength from the full dataset. This design choice matters because diagnostic performance can vary with factors such as infection intensity, population age structure, and the prevalence of other parasitic infections that might cross-react with the Ov16 antigen.

For the elimination community, the study offers both reassurance and a call to action. The demonstration that rigorous, assumption-aware evaluation of rapid diagnostic tests is feasible using Bayesian latent class methods provides a template for assessing future diagnostics, not only for onchocerciasis but for other diseases approaching elimination where gold standards are similarly lacking. At the same time, the finding that no evaluated test meets the specificity threshold on its own underscores that the final mile of the river blindness campaign will demand continued investment in diagnostic development. The GADx test’s sensitivity performance marks a milestone worth celebrating, but the road to confident, evidence-based decisions about stopping mass drug administration will require tools that are both more sensitive and more specific than anything currently in the field. Until then, program managers must weigh these imperfect instruments carefully, knowing that the health of millions and the credibility of the elimination enterprise rest on getting the answer right.

Subject of Research: Diagnostic accuracy of Ov16 rapid diagnostic tests for onchocerciasis elimination using Bayesian latent class models

Article Title: Assessing diagnostic accuracy of onchocerciasis rapid diagnostic tests using Bayesian latent class models

Article References: Norman, J., Bassabi-Alladjie, N.-M., Boko-Collins, P. M., de Souza, D. K., Gass, K., Hamill, L., Langa, J., Moore, C., Mucato, N., Nala, R., Sullivan, S., & Giorgi, E. (2026). Assessing diagnostic accuracy of onchocerciasis rapid diagnostic tests using Bayesian latent class models. PLOS Neglected Tropical Diseases, 20(10), e0013954. https://doi.org/10.1371/journal.pntd.0013954

Image Credits: AI Generated

DOI: 10.1371/journal.pntd.0013954

Keywords: onchocerciasis, river blindness, rapid diagnostic tests, Bayesian latent class models, Ov16 antigen, diagnostic accuracy, mass drug administration, neglected tropical diseases, GADx, SD BIOLINE, elimination, serology

A new study published in the journal Parasites & Vectors offers one of the first real-world tests of those guidelines. An international team of researchers, led by Sara Roose of IRCCS Sacro Cuore Don Calabria Hospital in Verona, Italy, together with colleagues from the Ethiopian Public Health Institute and Ghent University, set out to determine whether the WHO framework could be applied in practice using serological diagnostics. Their findings, drawn from nearly seven thousand blood samples collected across Ethiopia, suggest that the country’s burden of strongyloidiasis is highly uneven, and that a nationwide treatment campaign may be unnecessary while targeted interventions in specific districts could deliver substantial benefit.

The technical foundation of the study rests on banked serum samples originally collected in 2019 during a large epidemiological survey of soil-transmitted helminths. Rather than recruiting new participants, the researchers exploited this existing biobank, analyzing 6,693 samples from 63 schools spread across 33 woredas, the administrative districts that serve as implementation units for neglected tropical disease control in Ethiopia. This design allowed the team to generate district-level estimates of infection without the cost and logistics of a new national field campaign, demonstrating a pragmatic pathway that other endemic countries could follow.

Detecting S. stercoralis is notoriously difficult. Unlike other soil-transmitted worms, the parasite sheds larvae in feces only intermittently, so conventional stool microscopy such as the Kato-Katz thick smear, the workhorse of helminth mapping, misses most infections. The researchers instead turned to serology, using the commercially available InBios Strongy Detect IgG ELISA. This assay detects antibodies against two recombinant antigens, NIE and SsIR, which are specific to S. stercoralis. Because antibodies persist after infection, a positive result indicates exposure at some point, which makes serology well suited for mapping the geographic distribution of transmission even if it cannot distinguish current from past infection with perfect precision.

The results revealed an overall seroprevalence of 10.4 percent, with a 95 percent confidence interval of 9.7 to 11.1 percent. More striking than the national average was the heterogeneity between districts. Woreda-level seroprevalence ranged from a low of 2.7 percent to a high of 41.0 percent, a fifteen-fold difference that underscores how locally variable transmission can be. Under the WHO guidelines, mass drug administration with ivermectin should be considered in implementation units where observed seroprevalence among school-aged children exceeds 15 percent. Applying that threshold to the Ethiopian data, only seven of the 33 woredas qualified for targeted treatment.

The study also examined a second question with important programmatic implications: whether existing mass drug administration campaigns targeting other diseases had already suppressed strongyloidiasis as a collateral benefit. Ivermectin, the drug of choice for S. stercoralis, is widely distributed in Ethiopia through programs aimed at lymphatic filariasis and other filarial diseases. The researchers compared seroprevalence in woredas that had received ivermectin mass drug administration in the five years preceding sample collection, from 2014 to 2018, with those that had not. The pattern was striking: none of the woredas where ivermectin had been administered during that window exceeded the WHO threshold for initiating treatment.

These findings carry two major messages for policy. First, they suggest that Ethiopia does not require a dedicated nationwide mass drug administration program for strongyloidiasis. Instead, treatment could be confined to a selected number of woredas where seroprevalence is high, conserving resources and reducing the risk of unnecessary drug exposure. Second, the data provide evidence that existing ivermectin-based programs targeting filarial infections are already delivering hidden dividends against S. stercoralis, a benefit that has not historically been counted when the value of those campaigns is assessed. For ministries of health weighing the costs of neglected tropical disease programs, such collateral effects strengthen the economic case for sustained investment.

The authors are careful to acknowledge the limits inherent in their design. The samples were collected for a different purpose in 2019, so the estimates reflect the situation at that time rather than the present day. Seroprevalence measured in school-aged children serves as a proxy for community transmission, and antibody persistence means the assay may overestimate current infection in areas where transmission has recently declined. The study’s cross-sectional design also means the apparent protective association with prior ivermectin administration, while consistent with the biology of the drug, cannot be interpreted as definitive proof of causation. These caveats do not undermine the central conclusion, but they highlight the need for confirmation through prospective surveys.

Beyond the Ethiopian findings, the study exposes practical gaps that must be closed before serology-based mapping can be scaled up globally. The researchers emphasize that national health institutes need technical manuals that define survey designs accounting for the sensitivity and specificity of the diagnostic test used. Without such corrections, raw seroprevalence figures can mislead program managers about whether a district truly crosses the WHO treatment threshold. The team also calls on manufacturers of commercial serological assays to provide validated cutoffs, transparent performance characteristics, and clear statements of the target condition and target population for which those characteristics were derived. Meeting these requirements, the authors argue, will be essential for the reliable application of the new WHO guidelines using antibody-based diagnostics.

The Ethiopian experience offers a template for other endemic countries now confronting the question of how to implement WHO’s first strongyloidiasis guidelines. By leveraging banked samples, a commercially available ELISA, and the existing administrative structure of neglected tropical disease implementation units, the researchers showed that a credible national picture of S. stercoralis distribution can be assembled quickly and affordably. The image that emerges is not one of uniform national burden but of scattered hotspots coexisting with districts where transmission appears already controlled, partly through the unintended generosity of campaigns aimed at other parasites. For a disease that has spent decades in the shadows of global health, that level of geographic resolution is a significant step forward, and it transforms the abstract language of guidelines into a concrete map of where treatment is needed most.

Subject of Research: Seroprevalence of Strongyloides stercoralis infection and application of WHO public health control guidelines in Ethiopia

Article Title: Exploring the application of the WHO guidelines for the public health control of strongyloidiasis through a seroprevalence study in Ethiopia

Article References: Exploring the application of the WHO guidelines for the public health control of strongyloidiasis through a seroprevalence study in Ethiopia. (n.d.). https://doi.org/10.1186/s13071-026-07736-z

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07736-z

Keywords: Strongyloides stercoralis, strongyloidiasis, seroprevalence, WHO guidelines, Ethiopia, ELISA, ivermectin, mass drug administration, neglected tropical diseases, soil-transmitted helminths, public health control, serology

Lymphatic filariasis is a disfiguring and disabling neglected tropical disease caused by thread-like nematode worms, in this region primarily Brugia malayi, whose larval stages circulate in human blood and are picked up by mosquitoes during a blood meal. Although Indonesia has invested heavily in mass drug administration, delivering annual rounds of antiparasitic drugs to entire communities to drive down the parasite reservoir, the disease remains endemic in several island communities, and Belitung District has previously been flagged as an area at risk of recrudescence after the cessation of treatment campaigns. Understanding why transmission lingers in some places despite years of drug pressure is one of the central puzzles of the global elimination programme, and spatial epidemiology has emerged as one of the most promising tools for solving it.

The research team, led by Santoso Santoso of the Baturaja Public Health Laboratory Center with collaborators from Indonesia’s National Research and Innovation Agency and partner institutions, focused on two villages: Suak Gual, in Selat Nasik Subdistrict, and Lasar, in Membalong Subdistrict, the latter encompassing the sub-villages of Batumana, Dudat, and Ulin. In total, 671 residents participated in the survey. Because the parasites that cause brugian filariasis exhibit nocturnal periodicity, meaning their microfilariae surge into the peripheral bloodstream at night when their mosquito vectors are active, blood collection had to take place after dark. Thick blood smears were prepared from each participant and examined microscopically for the presence of parasites, providing a direct measure of who was infected and who was not.

Crucially, the team did not stop at counting cases. Using handheld GPS receivers, they recorded the precise coordinates of every participant’s residence, regardless of infection status, and mapped every water body in the study area that displayed characteristics consistent with a potential Mansonia breeding habitat. This ecological detail matters because Mansonia mosquitoes have an unusual and demanding larval biology: unlike many culicine mosquitoes that lay eggs on open water surfaces, Mansonia larvae attach their breathing siphons to the roots and stems of floating aquatic plants, drawing oxygen directly from the plant’s aerenchyma tissue. This means their breeding sites are defined not simply by standing water but by the presence of specific macrophyte vegetation, typically in swamps, ponds, and slow-moving water bodies, a constraint that makes their habitats discrete, mappable features of the landscape rather than diffuse environmental conditions.

With cases and habitats both geolocated, the researchers deployed a battery of spatial statistics to test whether the distribution of infections deviated from randomness. The Clark-Evans test, a classic nearest-neighbour analysis, compares the average distance between each case and its nearest neighbouring case with the distance expected if the points were distributed at random across the same area. An R statistic below 1 indicates clustering, values near 1 indicate randomness, and values above 1 indicate a regular, evenly spaced pattern. The team also applied the cross-K function, which extends this logic to two point patterns at once, asking whether cases and habitats are more closely associated with each other than chance would predict, and buffer zone analysis, which measures how many cases fall within set distances of the nearest habitat.

The results were striking. In Suak Gual, the Clark-Evans test returned an R value of 0.380 with a p-value below 0.001, indicating extremely strong clustering of cases, and in Batumana the R value of 0.432 was similarly significant. These findings held up after Bonferroni correction, a conservative statistical adjustment that raises the bar for significance when multiple tests are performed, and they remained robust across all boundary-window widths the researchers tested, a sensitivity check that guards against the possibility that the apparent clustering is an artefact of how the study area edges were defined. Ulin showed a nominally significant R value of 0.654 with p equal to 0.026, but this did not survive the Bonferroni correction, which raised the threshold to p equal to 0.106, nor a narrower boundary window, and the authors accordingly report it as a weaker and less consistent finding rather than a confirmed cluster.

Dudat told a different story altogether. There, the R value of 0.856 with a p-value of 0.434 indicated no significant deviation from spatial randomness, and the researchers attribute this to the sub-village’s comparatively dense and widespread distribution of potential habitats. The logic is intuitive: where breeding sites are everywhere, no single location confers an elevated risk, and cases accumulate broadly rather than concentrating in hotspots. This contrast between sub-villages is itself informative, because it suggests that the spatial signature of filariasis transmission is not a fixed property of the parasite or the human population but a function of the local ecology, varying with the abundance and arrangement of vector habitats across the terrain.

Perhaps the most operationally consequential number in the study is this: 76.5 percent of cases, 26 of the 34 infected individuals identified, lived within 500 metres of the nearest potential Mansonia habitat. That figure provides a concrete, defensible radius for intervention planning. Rather than treating an entire endemic village as a uniform risk zone, programmes could concentrate larval source management, environmental modification of aquatic plant habitats, and intensified surveillance on households within a half-kilometre buffer of mapped breeding sites. The approach aligns with a growing body of literature on residual transmission, the stubborn persistence of infection after mass drug administration, which modelling studies suggest is strongly shaped by the spatial aggregation of vectors and hosts. Where transmission is clustered, targeted vector control can achieve disproportionate reductions in risk for a given budget.

The study’s authors are careful about the limits of their evidence. The water bodies they mapped were classified as potential Mansonia habitats on the basis of their physical and ecological characteristics, not on the basis of mosquito larvae actually collected from them, and no entomological confirmation of vector presence or parasite infection in mosquitoes was performed. The survey was also cross-sectional, capturing a single moment in time, so it cannot establish the direction of causality or track how transmission dynamics unfold across seasons. Night-time blood smears, while the standard field method for detecting nocturnally periodic microfilariae, are less sensitive than modern antibody and antigen assays, meaning some low-level infections may have been missed. The researchers explicitly state that direct entomological surveys are still needed to confirm vector presence and to test the effectiveness of spatially targeted control in practice.

Even with those caveats, the study adds Belitung to a growing list of settings, from American Samoa to Ghana to Sri Lanka, where spatial analysis has exposed the heterogeneous geography of filariasis persistence and demonstrated that post-treatment surveillance can be made smarter by mapping. For a disease on the cusp of global elimination, the last kilometres are the hardest, and the tools that matter most are those that tell programmes precisely where to look. On this Indonesian island, the map now points toward the swamps and ponds where aquatic plants anchor the mosquito larvae that keep the parasite’s life cycle turning, and toward the households within walking distance of them, where the next phase of the elimination campaign may find its most valuable targets.

Subject of Research: Spatial clustering of lymphatic filariasis cases relative to potential Mansonia mosquito breeding habitats in endemic villages of Belitung Regency, Indonesia

Article Title: Spatial Clustering of Lymphatic Filariasis in Relation to Potential Mansonia Mosquito Habitats in Endemic Communities of Belitung Regency, Indonesia

Article References: Santoso, S., Suryaningtyas, N. H., Wigati, R. A., Sukendra, D. M., Yunarko, R., Widiastuti, D., Oktarina, R., Hidayat, S., Nurcahyo, W., & Ernawan, B. (2026). Spatial Clustering of Lymphatic Filariasis in Relation to Potential Mansonia Mosquito Habitats in Endemic Communities of Belitung Regency, Indonesia. Acta Parasitologica, 71(5), Article 230. https://doi.org/10.1007/s11686-026-01414-x

Image Credits: AI Generated

DOI: 10.1007/s11686-026-01414-x

Keywords: lymphatic filariasis, Brugia malayi, Mansonia, spatial analysis, Clark-Evans test, cross-K function, vector breeding habitats, Belitung, Indonesia, mass drug administration, neglected tropical diseases, spatial epidemiology